Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial

Fig. 1

TOCITAKA trial data of steroids sparing effect and relapse rates after 6-month tocilizumab therapy. a Steroids amounts during the 18-month follow-up in TOCITAKA trial. b Frequencies of relapse after 6-month tocilizumab induction therapy, represented as cumulative proportion of patients in remission and with relapsing-persistent TAK disease at months 3, 6, 9, and 12 after the tocilizumab discontinuation

Back to article page
\